Title:
METHOD FOR DETECTING THE ACTIVATABLE FREE FORM OF PSA AND THE USE THEREOF FOR DIAGNOSING BENIGN PATHOLOGIES OF THE PROSTATE AND ADENOCARCINOMA OF THE PROSTATE
Document Type and Number:
WIPO Patent Application WO2005085292
Kind Code:
A3
Abstract:
The invention relates to an in vitro diagnostic method for diagnosing a benign pathology of the prostate or an adenocarcinoma of the prostate characterized by comprising a step for detecting the activatable free form of PSA in a biological sample from a patient suspected of having developed a benign pathology of the prostate or an adenocarcinoma of the prostate. This diagnostic method can be carried out by the following steps consisting of: i) bringing a binding partner capable of specifically binding to the activatable free PSA in contact with a biological sample from a patient suspected of having developed a benign pathology of the prostate or an adenocarcinoma of the prostate; ii) detecting the capture of the activatable free form of PSA by said binding partner; iii) calculating the ratio between the quantity of the activatable free form of PSA detected in step ii) and the quantity of a form of PSA other than the activatable free form present in a sample of the same type taken from the same subject, and; iv) determining if the patients are affected by an adenocarcinoma of the prostate or by a benign pathology of the prostate by comparing the value of the ratio determined in step iii) with a predetermined threshold value selected according to the type of ratio used and representative of the detection limit of each pathology.
Inventors:
BUSSERET-MICHEL SANDRINE (FR)
JOLIVET-REYNAUD COLETTE (FR)
JOLIVET-REYNAUD COLETTE (FR)
Application Number:
PCT/FR2005/050132
Publication Date:
February 09, 2006
Filing Date:
March 01, 2005
Export Citation:
Assignee:
BIOMERIEUX SA (FR)
BUSSERET-MICHEL SANDRINE (FR)
JOLIVET-REYNAUD COLETTE (FR)
BUSSERET-MICHEL SANDRINE (FR)
JOLIVET-REYNAUD COLETTE (FR)
International Classes:
G01N33/574; (IPC1-7): G01N33/574; C07K16/40
Domestic Patent References:
| WO2001077180A1 | 2001-10-18 | |||
| WO2000002052A1 | 2000-01-13 | |||
| WO2001096876A1 | 2001-12-20 |
Other References:
MICHEL S. ET AL.: "Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling.", CLIN. CHEM., vol. 45, no. 5, May 1999 (1999-05-01), pages 638 - 650, XP002175112
COREY E. ET AL.: "LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.", THE PROSTATE, vol. 35, 1998, pages 135 - 143, XP000981985
LILJA H.: "Biology of prostate-specific antigen.", UROLOGY, vol. 62, no. 5, November 2003 (2003-11-01), pages 27 - 33, XP002286825
MICHEL S. ET AL.: "Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.", J. MOL. RECOGNIT., vol. 18, no. 3, May 2005 (2005-05-01), pages 225 - 235, XP009055674
COREY E. ET AL.: "LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.", THE PROSTATE, vol. 35, 1998, pages 135 - 143, XP000981985
LILJA H.: "Biology of prostate-specific antigen.", UROLOGY, vol. 62, no. 5, November 2003 (2003-11-01), pages 27 - 33, XP002286825
MICHEL S. ET AL.: "Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.", J. MOL. RECOGNIT., vol. 18, no. 3, May 2005 (2005-05-01), pages 225 - 235, XP009055674
Download PDF: